We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An arbitration panel has ordered Barr Pharmaceuticals to pay $68 million to drugmaker Solvay Pharmaceuticals after ruling that Barr’s subsidiary Duramed Pharmaceuticals improperly ended a contract to co-promote products with Solvay.
The House passed sweeping legislation yesterday that would provide tax relief to all U.S. corporations, including drug manufacturers, that do business abroad.
A bill approved by the Senate late Tuesday to end European trade sanctions against U.S. businesses would extend by 18 months a research and development (R&D) corporate tax credit set to expire June 30, according to an official at a manufacturing trade group whose members include PhRMA and the Biotechnology Industry Organization.
Higher average clinical research and development (R&D) costs for drugs in some therapeutic classes are helping create an incentive for drugmakers to shift their efforts among disease states, according to a new study by the Tufts Center for the Study of Drug Development (CSDD).
Rather than curtailing services, the FDA plans to consolidate the agency’s 16 existing drug review centers into just three centers at the White Oak campus in Maryland, which should increase productivity and boost performance, according to an FDA spokesperson.
The Bush administration is requesting funding of $1.49 billion for the FDA in fiscal 2005 and $350 million in drug industry user fees, according to FDA acting Commissioner Lester Crawford.
A breakdown of the FDA’s proposed budget for fiscal 2005, which represents an increase of $149 billion over last year’s appropriations, reveals that the agency wants to tap into industry user fees, rather than congressionally approved funding, to pay for most of its new full-time employees.
The FDA would get $1.8 billion in fiscal 2005, with the lion’s share of the $149 million increase over last year’s appropriations going to food safety rather than toward programs affecting the drug industry, according to details of President Bush’s proposed budget that was released last week.
Some members of the generic drug industry are vowing to lobby for more funding for FDA’s Office of Generic Drugs (OGD) if it becomes clear the agency isn’t able to handle an increasing workload with a Bush-administration proposed fiscal 2005 budget that keeps funding levels flat.